GI Innovation adds Australia HREC approval to GI-102 Phase 1/2 trial plan amendment disclosure

• GI Innovation issued a correction to its disclosure on the GI-102 Phase 1/2 trial protocol modification.
• The update adds Australia to the trial footprint following approval from Bellberry Human Research Ethics Committee (HREC) on 2026-10-01.
• Australia is now listed alongside South Korea, the U.S. for trial oversight, with Melanoma Institute Australia added as a study site.
• The corrected filing also adds an Australian application number: 2025-07-1189.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GI Innovation Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261001900361), on October 01, 2026, and is solely responsible for the information contained therein.